Poster 553: HUB Organoids™ improve preclinical toxicology, metabolism, and pharmacokinetic studies for drug discovery and development
Discover our latest data on the application of HUB Organoids to the preclinical evaluation of a compound safety and ADME profile.
Discover how to fast track your safety and ADME studies
Read our poster
Drug safety assessment at the preclinical stage is hampered by a lack of in vitro models that recapitulate healthy tissue physiology and gene expression for the evaluation of on- and off-target effects, drug metabolism, and pharmacokinetics (PK). Preclinical studies using animal model are costly and not always translatable to humans. On the other hand, standard patient-derived in vitro models such as primary cells have limited availability, expansion capacity, and are not stable in culture for experimental testing. Therefore there remains a need for advanced systems that can offer patient relevance and scalability to address drug toxicology, metabolism, and PK.
Here we show that:
- Differentiated human liver organoids are promising models to study drug-induced liver injury and drug metabolism
- HUB Organoids can differentiate interspecies and regional toxicity differences as expected from in vivo studies
- HUB Organoids can predict toxicity of a test compound with different modes of action